Characterization and selective crystallization of famotidine polymorphs

Journal of Pharmaceutical Sciences

Volumn 96, Issue 9, 2007, Pages 2457-2468

  Lu, Jie ^a   Wang, Xiu Juan ^a   Yang, Xia ^a   Ching, Chi Bun ^a  

^a Nanyang Technological University   (Singapore)

Author keywords

Characterization; Crystallization; Famotidine; Nucleation; Polymorph; Polymorphic window; Solid state; Solubility; Thermodynamics

Indexed keywords

ACETONITRILE; FAMOTIDINE; METHANOL; WATER;

AQUEOUS SOLUTION; ARTICLE; CONFORMATIONAL TRANSITION; COOLING; CRYSTALLIZATION; DRUG SELECTIVITY; DRUG SOLUBILITY; SOLID STATE; THERMODYNAMICS; X RAY DIFFRACTION;

EID: 34748893096     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20868     Document Type: Article

References (51)

1. Grant DJW. 1999. Theory and origin of polymorphism. In: Brittain HG, editor. Polymorphism in pharmaceutical solids. New York: Marcel Dekker, Inc. pp 1-34.
2. Henck JO, Griesser UJ, Burger A. 1997. Polymorphism of drug substances - an economic challenge. Pharm Ind 59:165-169.
3. Beckmann W, Otto W, Budde U. 2001. Crystallization of the stable polymorph of hydroxytriendione: Seeding process and effects of purity. Org Process Res Dev 5:387-392.
4. Ferrari ES, Davey RJ. 2004. Solution-mediated transformation of α to β L-glutamic acid: Rate enhancement due to secondary nucleation. Cryst Growth Des 4:1061-1068.
5. Ostwald W. 1897. Studien über die bildung und Umwandlung fester körper. Z Phys Chem 22:289-330.
6. Bernstein J. 2002. Polymorphism in molecular crystals. Oxford: Clarendon Press.
7. Teychené S, Autret JM, Biscans B. 2004. Crystallization of eflucimibe drug in a solvent mixture: Effects of process conditions on polymorphism. Cryst Growth Des 4:971-977.
8. Vivares D, Veesler S, Astier JP, Bonnete F. 2006. Polymorphism of urate oxidase in PEG solutions. Cryst Growth Des 6:287-292.
9. Jones HP, Davey RJ, Cox BG. 2005. Crystallization of a salt of a weak organic acid and base: Solubility relations, supersaturation control and polymorphic behavior. J Phys Chem B 109:5273-5278.
10. Groen H, Roberts KJ. 2001. Nucleation, growth, and pseudo-polymorphic behavior of citric acid as monitored in situ by attenuated total reflection Fourier transform infrared spectroscopy. J Phys Chem B 105:10723-10730.
11. Beckmann W. 2000. Seeding the desired polymorph: Background, possibilities, limitations, and case studies. Org Process Res Dev 4:372-383.
12. Donnet M, Bowen P, Jongen N, Lemaitre J, Hofmann H. 2005. Use of seeds to control precipitation of calcium carbonate and determination of seed nature. Langmuir 21:100-108.
13. Laird T. 2000. Special feature section: Polymorphism and crystallization. Org Process Res Dev 4:370-371.
14. Weissbuch I, Addadi L, Lahav M, Leiserowitz L. 1991. Molecular recognition at crystal interfaces. Science 253:637-645.
15. Davey RJ, Blagden N, Potts GD, Docherty R. 1997. Polymorphism in molecular crystals: Stabilization of a metastable form by conformational mimicry. J Am Chem Soc 119:1767-1772.
16. Agarwal P, Berglund KA. 2003. In situ monitoring of calcium carbonate polymorphs during batch crystallization in the presence of polymeric additives using Raman spectroscopy. Cryst Growth Des 3: 941-946.
17. Lu JJ, Ulrich J. 2003. An improved prediction model of morphological modifications of organic crystals induced by additives. Cryst Res Technol 38:63-73.
18. Lang MD, Grzesiak AL, Matzger AJ. 2002. The use of polymer heteronuclei for crystalline polymorph selection. J Am Chem Soc 124:14834-14835.
19. Price CP, Grzesiak AL, Matzger AJ. 2005. Crystalline polymorph selection and discovery with polymer heteronuclei. J Am Chem Soc 127:5512-5517.
20. Bonafede SJ, Ward MD. 1995. Selective nucleation and growth of an organic polymorph by ledge-directed epitaxy on a molecular-crystal substrate. J Am Chem Soc 117:7853-7861.
21. Mitchell CA, Yu L, Ward MD. 2001. Selective nucleation and discovery of organic polymorphs through epitaxy with single crystal substrates. J Am Chem Soc 123:10830-10839.
22. Hiremath R, Varney SW, Swift JA. 2004. Selective growth of a less stable polymorph of 2-iodo-4-nitroaniline on a self-assembled monolayer template. Chem Commun 2676-2677.
23. Zaccaro J, Matic J, Myerson AS, Garetz BA. 2001. Nonphotochemical, laser-induced nucleation of supersaturated aqueous glycine produces unexpected γ-polymorph. Cryst Growth Des 1:5-8.
24. Trask AV, Motherwell WDS, Jones W. 2004. Solvent-drop grinding: Green polymorph control of cocrystallisation. Chem Commun 890-891.
25. Yu L, Ng K. 2002. Glycine crystallization during spray drying: The pH effect on salt and polymorphic forms. J Pharm Sci 91:2367-2375.
26. Beach S, Latham D, Sidgwick C, Hanna M, York P. 1999. Control of the physical form of salmeterol xinofoate. Org Process Res Dev 3:370-376.
27. Hilden JL, Reyes CE, Kelm MJ, Tan JS, Stowell JG, Morris KR. 2003. Capillary precipitation of a highly polymorphic organic compound. Cryst Growth Des 3:921-926.
28. Childs SL, Chyall LJ, Dunlap JT, Coates DA, Stahly BC, Stahly GP. 2004. A metastable polymorph of metformin hydrochloride: Isolation and characterization using capillary crystallization and thermal microscopy techniques. Cryst Growth Des 4:441-449.
29. Ha JM, Wolf JH, Hillmyer MA, Ward MD. 2004. Polymorph selectivity under nanoscopic confinement. J Am Chem Soc 126:3382-3383.
30. Gracin S, Rasmuson ÅC. 2004. Polymorphism and crystallization of p-aminobenzoic acid. Cryst Growth Des 4:1013-1023.
31. Morissette SL, Almarsson Ö, Peterson ML, Remenar JF, Read MJ, Lemmo AV, Ellis S, Cima MJ, Gardner CR. 2004. High-throughput crystallization: Polymorphs, salts, co-crystals and solvates of pharmaceutical solids. Adv Drug Deliver Rev 56:275-300.
32. Hegedus B, Bod P, Harsányi K, Péter I, Kálmán A, Párkányi L. 1989. Comparison of the polymorphic modifications of famotidine. J Pharmaceut Biomed 7:563-569.
33. Overgaard J, Hibbs DE. 2004. The experimental electron density in polymorphs A and B of the antiulcer drug famotidine. Acta Cryst A 60:480-487.
34. Ferenczy GG, Párkányi L, Ángyán JG, Kálmán A, Hegedus B. 2000. Crystal and electronic structure of two polymorphic modifications of famotidine: An experimental and theoretical study. J Mol Struct (Theochem) 503:73-79.
35. Stoica C, Tinnemans P, Meekes H, Vlieg E. 2005. Epitaxial 2D nucleation of metastable polymorphs: A 2D version of Ostwald's rule of stages. Cryst Growth Des 5:975-981.
36. Datta S, Grant DJW. 2005. Effect of supersaturation on the crystallization of phenylbutazone polymorphs. Cryst Res Technol 40:233-242.
37. Söhnel O, Garside J. 1992. Precipitation. Oxford: Butterworth-Heinemann.
38. Tong HHY, Shekunov BY, York P, Chow AHL. 2002. Influence of polymorphism on the surface energetics of salmeterol xinafoate crystallized from supercritical fluids. Pharmaceut Res 19:640-648.
39. Sato K, Boistelle R. 1984. Stability and occurrence of polymorphic modifications of stearic-acid in polar and nonpolar solutions. J Cryst Growth 66:441-450.
40. Yu L, Reutzel-Edens SM, Mitchell CA. 2000. Crystallization and polymorphism of conformationally flexible molecules: Problems, patterns, and strategies. Org Process Res Dev 4:396-402.
41. Threlfall T. 2003. Structural and thermodynamic explanations of Ostwald's Rule. Org Process Res Dev 7:1017-1027.
42. Threlfall T. 2000. Crystallisation of polymorphs: Thermodynamic insight into the role of solvent. Org Process Res Dev 4:384-390.
43. Gu CH, Young V, Grant DJW. 2001. Polymorph screening: Influence of solvents on the rate of solvent-mediated polymorphic transformation. J Pharm Sci 90:1878-1890.
44. Weissbuch I, LahavM, Leiserowitz L. 2003. Toward stereochemical control, monitoring, and understanding of crystal nucleation. Cryst Growth Des 3:125-150.
45. Mullin JW. 1993. Crystallization, 3rd edition. London: Butterworth-Heinemann.
46. Wireko FC, Shimon LJW, Frolow F, Berkovitch-Yellin Z, Lahav M, Leiserowitz L. 1987. Effect of solvent on the growth of organic-crystals 1: The riddle of alpha-resorcinol. J Phys Chem 91:472-481.
47. Kamlet MJ, Dickinson C. 1982. Dipole contribution to formation constants of some "hydrogen bonded complexes". J Org Chem 47:4971-4975.
48. Davey RJ, Allen K, Blagden N, Cross WI, Lieberman HF, Quayle MJ, Righini S, Seton L, Tiddy GJT. 2002. Crystal engineering - nucleation, the key step. Cryst Eng Comm 4:257-264.
49. Mirmehrabi M, Rohani S. 2005. An approach to solvent screening for crystallization of polymorphic pharmaceuticals and fine chemicals. J Pharm Sci 94:1560-1576.
50. Gu CH, Li H, Gandhi RB, Raghavan K. 2004. Grouping solvents by statistical analysis of solvent property parameters: Implication to polymorph screening. Int J Pharm 283:117-125.
51. Golič L, Djinović K, Florjanič M. 1989. Structure of a new crystalline form of famotidine. Acta Cryst C 45:1381-1384.